Denali Therapeutics Inc (DNLI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $19.82 (-1.54%), Market cap $2.87B, 52-week low–high $12.75 ~ $22.74.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler
Financial statements, price targets, institutional (13F) holdings and related news for Denali Therapeutics Inc are updated in real time on BlackAll Trade.
Denali Therapeutics Inc trades at $19.82 (-1.54%). Real-time quotes and charts are available on BlackAll Trade.
Denali Therapeutics Inc has a market cap of about $2.87B.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL75